INN Working Document 13.333 rev. P
ENGLISH ONLY
28/10/2013

Pre-stems:*
Suffixes used in the selection of INN
October 2013

Programme on International Nonproprietary Names (INN)

Technologies Standards and Norms (TSN)

World Health Organization,
Geneva

© World Health Organization (2013) -This document is not issued to the general public, and all rights are reserved by the World Health Organization (WHO). The document may not be reviewed, abstracted, quoted, reproduced or translated, in part or in whole, without the prior written permission of WHO. No part of this document may be stored in a retrieval system or transmitted in any form or by any means - electronic, mechanical or other - without the prior written permission of WHO. The views expressed in documents by named authors are solely the responsibility of those authors.

**The prestems given have been flagged because they may be selected as official stems ("The use of stems in the selection of International Nonproprietary Names for Pharmaceutical Substances", 2013, WHO/EMP /RHT/TSN/2013.1). At present, they are made available for information and potential guidance to the applicants.*

stem	*definition*
-suffix	
-infix-	

In bold: new pre-stems selected during the 57th INN Consultation.
In bold and underlined: Pre-stems newly promoted to Stems status

---

-algron	α_1-adrenoreceptor agonists
-ampator	amino-hydroxymethyl-isoxazole-propionic acid (AMPA) receptor modulators
-apt-	aptamers, classical and mirror ones
-ast	*antiasthmatics, antiallergics, not acting primarily as antihistaminics*
-tegr-	**integrin antagonists**
-asvir	see *vir*
-axomab	see *mab*
-berel	beta estrogen receptor agonists
-brutinib	see *tinib*
-calcet/-calcet-	Calcium-Sensing Receptors (CaSR) agonists
-camra	intracellular adhesion molecule, ICAM-1 derivatives
-casan	caspase (interleukin-1b) converting enzyme inhibitors
-caserin	serotonin receptor agonists (mostly 5-HT_2)
-catib	cathepsin inhibitors
-ciclib	**cyclin dependant kinase inhibitors**
-citinib	see *-tinib*
-closporin	ciclosporin derivatives
-codar	see *dar*
-corat	*glucocorticoid receptor agonists*
-cridar	see *dar*

dar	*drugs used in multidrug resistance*
-cri-	acridinecarboxamide derivatives
-co-	pipecolinate derivatives
-spo-	ciclosporin D derivatives
-degib	SMO receptor antagonists
-depsin	depsipeptide derivatives
-domide	antineoplastics, thalidomide derivatives
-dotin	synthetic derivatives of dolastatin series
-ectedin	ecteinascidin derivatives
-estrant	estrogen antagonists
-farnib	farnesyl transferase inhibitors
-fensine	norepinephrine, serotonin, dopamine reuptake inhibitors
-fibatide	see *tide*
-fulven	antineoplastic, acylfulven derivatives
-gacestat	see *-stat*
-ganan	antimicrobial, bactericidal permeability increasing polypeptides
-gepant	calcitonin gene-related peptide receptor antagonists
-glurant	metabotropic glutamate receptors antagonists / negative
-gapil	neuronal apoptosis inhibitors, GAPDH
-imepodib	inosine monophosphate dehydrogenase inhibitors
-isant	histamine H_3 receptor antagonists
-kalner	openers of calcium-activated (maxi-K) K^+-channels

-laner	**antagonists of GABA (gamma-aminobutyric acid) regulated chloride channels, antiparasitic agents**
-leptin(e)	leptin derivatives
mab	*monoclonal antibodies*
-axo-	rat-murine hybrid antibodies
-metinib	see *tinib*
-moren	non-peptidic growth hormone secretagogues
-nepag	prostaglandins receptors agonists, non-prostanoids
-nesib	kinesin inhibitors
-neurin	neurotrophins
nil	*benzodiazepine receptor antagonists/agonists*
-punil	mitochondrial benzodiazepine receptor (MBR)- selective agonists also partial or inverse (purine derivatives)
-opran	μ-opioid receptors antagonists
-orexant	orexin receptor antagonists
-osuran	urotensin receptor antagonists
-otilate	hepatoprotectants, diisopropyl-1,3-dithiol-malonate derivatives
-patril/-patrilat	see *tril/trilat*
-paxar	protease activated receptor type 1 (PAR1) antagonists
-piprant	**prostaglandins receptors antagonists, non-prostanoids**

预览已结束，完整报告链接和二维码如下：
https://www.yunbaogao.cn/report/index/report?reportId=5_28055